scPharmaceuticals Inc.
Commercializes subcutaneous drug-device therapies for at-home cardiorenal care.
SCPH | NDAQ
Overview
Corporate Details
- ISIN(s):
- US8106481059
- LEI:
- Country:
- United States of America
- Address:
- 25 BURLINGTON MALL ROAD, SUITE 203, 1803 BURLINGTON
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
scPharmaceuticals Inc. is a commercial-stage pharmaceutical company, operating as a subsidiary of MannKind Corporation, focused on developing and commercializing patient-centric treatments for cardiorenal diseases. The company specializes in drug-device combinations that facilitate subcutaneous drug delivery, aiming to improve patient outcomes and shift care from clinical settings to the home. Its flagship product, FUROSCIX®, is a proprietary formulation of furosemide delivered via an auto-injector for treating congestion in patients with heart failure and, as of 2025, chronic kidney disease. The company's strategy centers on creating value-based solutions that reduce the burden of care and enhance quality of life for patients with cardiovascular and renal conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all scPharmaceuticals Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for scPharmaceuticals Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for scPharmaceuticals Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||